We are a specialty pharmaceutical company with one approved proprietary product, SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system and one proprietary product candidate in late-stage development for the treatment of central nervous system disorders and pain. SUMAVEL DosePro enables subcutaneous delivery of sumatriptan without a needle for the acute treatment of migraine attacks, with or without aura, and cluster headache episodes. We received approval from the FDA in July 2009 for SUMAVEL DosePro. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. We have initiated Phase 3 development for ZX002.